May 14, 2024 / 02:00PM GMT
Operator
Greetings, and welcome to the Nykode Therapeutics Q1 2024 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded.
Is now my pleasure to introduce Chief Executive Officer, Michael Engsig. Thank you. You may begin.
Michael Engsig - Nykode Therapeutics ASA - Chief Executive Officer
Thank you very much, Darryl and all the participants. A very warm welcome to this Q1 report that we assume you're all familiar with our forward-looking statement. And on that note we'll move forward, I am very pleased to have with me here today are Agnete Fredriksen, our Chief Scientific Officer, Head of Business Development and Co-Founder; Harald Gurvin, our Chief Financial Officer; and Klaus Edvardsen, our Chief Research and Development Officer. And together, we will take you through the highlights of the quarter as well as the financial results.
A quick look as an introduction from my side. First quarter was yet another exciting quarter with very solid progress for Nykode. We presented the very important top line
Q1 2024 Nykode Therapeutics ASA Earnings Call Transcript
May 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers